Activating this signaling pathway, known as the cGAS-STING pathway, worked even better when combined with existing immunotherapy drugs known as checkpoint blockade inhibitors, in a study of mice. That dual treatment was successfully able to control tumor growth.

The researchers turned on the cGAS-STING pathway in immune cells using messenger RNA delivered to cancer cells. This approach may avoid the side effects of delivering large doses of a STING activator, and takes advantage of a natural process in the body. This could make it easier to develop a treatment for use in patients, the researchers say.